TACE + Sorafenib Delays HCC Progression in Patients with Chronic HCV Infection

Share this content:

(ChemotherapyAdvisor) – Transarterial chemoembolization (TACE) with sequential sorafenib delayed time to progression (TTP) of intermediate-stage hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection, a prospective randomized study concluded in The Oncologist online February 14.

The study enrolled 80 patients with Barcelona Clinic Liver Cancer stage B HCC, Child-Pugh class A disease, and HCV infection. All underwent TACE and were randomized 1:1 to receive sorafenib 400mg twice daily or placebo. Endpoints were TTP and rates of adverse events and toxicity.

Of the 62 patients evaluable, median TTP was 9.2 months in the sorafenib group (n=31) and 4.9 months in the placebo group (n=31) (HR=2.5; P<0.001). “Metachronous, multicentric HCC progression occurred less frequently in sorafenib-treated patients,” the authors noted. Nine patients (22%) in the sorafenib group withdrew from the study due to adverse events.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs